Oryzon Genomics S.A. (ORYZF)
USD 3.03
(-0.66%)
USD 3.03
(-0.66%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 13.94 Million EUR | -9.03% |
| 2022 | 30.93 Million EUR | 51.0% |
| 2021 | 20.48 Million EUR | 10.63% |
| 2020 | 18.51 Million EUR | -8.0% |
| 2019 | 20.12 Million EUR | 210.18% |
| 2018 | 6.48 Million EUR | 60.39% |
| 2017 | 4.04 Million EUR | -12.79% |
| 2016 | 4.63 Million EUR | -32.06% |
| 2015 | 6.82 Million EUR | -55.07% |
| 2014 | 15.19 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | - USD | -100.0% |
| 2024 Q2 | 3.93 Million EUR | 0.0% |
| 2024 Q3 | - EUR | -100.0% |
| 2023 Q3 | 3.41 Million EUR | -6.95% |
| 2023 Q2 | 3.66 Million EUR | -0.86% |
| 2023 Q1 | 3.69 Million EUR | 12210.71% |
| 2023 FY | 13.94 Million EUR | -54.91% |
| 2023 Q4 | 3.18 Million EUR | -6.66% |
| 2022 Q1 | 3.33 Million EUR | 0.0% |
| 2022 Q2 | -44.46 Thousand EUR | -101.33% |
| 2022 FY | 30.93 Million EUR | 51.0% |
| 2022 Q3 | -43.47 Thousand USD | 2.23% |
| 2022 Q4 | -30.52 Thousand EUR | 29.78% |
| 2021 Q2 | 1.72 Million EUR | -37.77% |
| 2021 FY | 20.48 Million EUR | 10.63% |
| 2021 Q3 | - USD | -100.0% |
| 2021 Q1 | 2.77 Million EUR | 29.71% |
| 2021 Q4 | - USD | 0.0% |
| 2020 Q2 | 1.96 Million EUR | -43.45% |
| 2020 FY | 18.51 Million EUR | -8.0% |
| 2020 Q4 | 2.14 Million EUR | 51.68% |
| 2020 Q3 | 1.41 Million EUR | -28.15% |
| 2020 Q1 | 3.47 Million EUR | 23.61% |
| 2019 Q2 | 2.23 Million EUR | 14.74% |
| 2019 Q1 | 1.95 Million EUR | 11.21% |
| 2019 Q4 | 2.81 Million EUR | -1.28% |
| 2019 FY | 20.12 Million EUR | 210.18% |
| 2019 Q3 | 2.84 Million EUR | 27.29% |
| 2018 FY | 6.48 Million EUR | 60.39% |
| 2018 Q2 | 1.56 Million EUR | -9.46% |
| 2018 Q3 | 1.43 Million EUR | -8.22% |
| 2018 Q4 | 1.75 Million EUR | 21.96% |
| 2018 Q1 | 1.73 Million EUR | 168.01% |
| 2017 Q4 | 645.61 Thousand EUR | -38.14% |
| 2017 Q2 | 1.22 Million EUR | 8.78% |
| 2017 Q1 | 1.12 Million EUR | -10.27% |
| 2017 FY | 4.04 Million EUR | -12.79% |
| 2017 Q3 | 1.04 Million EUR | -14.97% |
| 2016 Q2 | 897.09 Thousand EUR | -25.12% |
| 2016 FY | 4.63 Million EUR | -32.06% |
| 2016 Q1 | 1.19 Million EUR | -3.37% |
| 2016 Q4 | 1.25 Million EUR | -2.19% |
| 2016 Q3 | 1.28 Million EUR | 43.32% |
| 2015 Q3 | 1.36 Million EUR | -55.17% |
| 2015 Q4 | 1.23 Million EUR | -9.43% |
| 2015 FY | 6.82 Million EUR | -55.07% |
| 2015 Q1 | 1.16 Million EUR | 0.0% |
| 2015 Q2 | 3.05 Million EUR | 162.14% |
| 2014 FY | 15.19 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ContraFect Corporation | -154 Thousand USD | 9157.087% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 7.008% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -449542.618% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -42.413% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -21120.658% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -19.152% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 88.29% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 40943.086% |
| Marizyme, Inc. | 457.7 Thousand USD | -2947.379% |
| Genus plc | 178.7 Million USD | 92.195% |
| Pharming Group N.V. | 220.1 Million USD | 93.663% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -22314.929% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -3300.562% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 126899.218% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -18070.574% |
| IMV Inc. | -962.29 Thousand USD | 1549.438% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 3699.452% |
| ONE Bio Corp. | 20.12 Million USD | 30.695% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 65.36% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 90529.94% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 68.556% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -19825.591% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 11325.595% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Mesoblast Limited | -35.16 Million USD | 139.661% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 281762.237% |
| Arch Therapeutics, Inc. | -2439.00 USD | 571970.193% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -9827.341% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 14403.352% |
| GB Sciences, Inc. | -624.00 USD | 2235342.628% |
| MultiCell Technologies, Inc. | 49.32 USD | -28280342.011% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 16313.226% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.816% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 6705827.885% |
| Enzolytics Inc. | 30.7 Thousand USD | -45321.109% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -2791.161% |
| argenx SE | 1.1 Billion USD | 98.742% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 50.636% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | -8285.00 USD | 168451.406% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 157596.771% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 16734.562% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 96.594% |
| Kadimastem Ltd | -630.13 Thousand USD | 2313.47% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -1311.759% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 1321.816% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -45.124% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 27995.828% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -28423.342% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | -8988.00 USD | 155283.734% |
| LadRx Corporation | -11.83 Thousand USD | 117953.097% |
| Cell Source, Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 29002.203% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -7799.815% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 154.066% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 2810.912% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -2159.196% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | 9.575% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -2999.24% |
| SYBLEU INC | 11.69 Thousand USD | -119153.711% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 4465.449% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -7799.815% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -927.741% |
| Mobile Lads Corp. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -202.689% |
| CytoDyn Inc. | -29 Thousand USD | 48196.255% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 3839.387% |
| Neutra Corp. | 14.33 Thousand USD | -97199.714% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 17109.651% |
| PureTech Health plc | -1.6 Million USD | 970.113% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 1493.07% |
| IXICO plc | 3.27 Million USD | -326.542% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 2109.786% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 878.778% |
| CSL Limited | 7.7 Billion USD | 99.819% |
| Cellectis S.A. | 18 Thousand USD | -77388.411% |